ERAS News and Press, Erasca Inc. From 03/23/23

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials for ERAS-007, ERAS-601, and ERAS-801 ...

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present a poster ...

Summary Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance and other macroeconomic issues. Erasca has some positive catalysts that co...

Summary Two new Breakout Stocks for Week 6 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +28.2% YTD. This week 3 of 4 high-frequency breakout picks gained over 10% in less than a week with peak gains in TOUR +20.3%, RIVN +12.8%, JMI...

Erasca ( NASDAQ: ERAS ) shares added ~7% in the morning hours Friday after Morgan Stanley upgraded the cancer-focused biotech to Overweight from Equal Weight, highlighting the RAF inhibitor naporafenib the company recently licensed from Novartis ( NVS ) ( OTCPK:NVSEF ). Th...

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim...

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41 st ...

Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therap...

Erasca ( NASDAQ: ERAS ) said on Tuesday the United States Food and Drug Administration had cleared an investigational new drug ( IND ) application for its oral drug, ERAS-3490, to treat KRAS G12C-mutated solid tumors, including non-small cell lung cancer. ERAS-3490 has de...

SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Adm...